List of Excipients in Branded Drug RYTHMOL

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GlaxoSmithKline LLC	RYTHMOL	propafenone hydrochloride	0173-0823	FERRIC OXIDE RED
GlaxoSmithKline LLC	RYTHMOL	propafenone hydrochloride	0173-0823	GELATIN
GlaxoSmithKline LLC	RYTHMOL	propafenone hydrochloride	0173-0823	HYPROMELLOSE
GlaxoSmithKline LLC	RYTHMOL	propafenone hydrochloride	0173-0823	LECITHIN, SOYBEAN
GlaxoSmithKline LLC	RYTHMOL	propafenone hydrochloride	0173-0823	MAGNESIUM STEARATE

Rythmol Excipient Strategy and Commercial Opportunities for Propafenone Products

Last updated: September 24, 2026

Rythmol is the branded formulation of propafenone hydrochloride, a Class IC antiarrhythmic used for selected patients with paroxysmal atrial fibrillation or flutter and paroxysmal supraventricular tachycardia. Its commercial opportunity is concentrated in generic immediate-release tablets, extended-release capsules, reformulated delivery systems, and excipient-enabled bioequivalence strategies. The original brand franchise has limited patent leverage because propafenone’s core composition and use patents are mature, while formulation and manufacturing know-how remain relevant to product differentiation.

What dosage forms and excipients are used in Rythmol products?

Rythmol is marketed in two principal oral dosage forms: immediate-release tablets and Rythmol SR extended-release capsules. The products use different excipient strategies because the tablet is designed for rapid systemic release, while the capsule controls propafenone exposure over an extended dosing interval.

Rythmol immediate-release tablets

Rythmol immediate-release tablets are available in 150 mg, 225 mg, and 300 mg strengths. Public FDA labeling identifies excipients including microcrystalline cellulose, corn starch, hypromellose, magnesium stearate, polyethylene glycol, polysorbate 80, sodium starch glycolate, talc, and titanium dioxide, with variations associated with tablet coating and presentation.[1]

The functional roles are:

Excipient	Primary function in Rythmol tablets	Commercial relevance
Microcrystalline cellulose	Diluent and compression aid	Supports robust tablet manufacture across dose strengths
Corn starch	Diluent and disintegrant	Promotes tablet breakup and contributes to low-cost manufacture
Sodium starch glycolate	Superdisintegrant	Controls disintegration and early drug release
Hypromellose	Binder or film former	Improves tablet integrity and coating performance
Magnesium stearate	Lubricant	Reduces punch and die friction
Polyethylene glycol	Coating plasticizer or solubilizing aid	Supports film flexibility and appearance
Polysorbate 80	Surfactant	Supports wetting and dispersion
Talc	Glidant or coating component	Improves powder flow and coating performance
Titanium dioxide	Opacifier and colorant	Supports product identification and light protection

The formulation has a conventional immediate-release architecture. The main development risk is not complex release control but maintaining dissolution, content uniformity, mechanical strength, and consistent exposure across strengths.

Rythmol SR extended-release capsules

Rythmol SR is supplied as extended-release capsules in 225 mg, 325 mg, and 425 mg strengths. FDA labeling identifies a multiparticulate capsule design in which the active ingredient is incorporated into extended-release pellets or particles contained within a hard gelatin capsule.[2]

The excipient platform includes controlled-release matrix or coating materials, microcrystalline cellulose, hypromellose, povidone, magnesium stearate, sodium lauryl sulfate, and capsule-shell components such as gelatin, titanium dioxide, and approved colorants. The exact qualitative and quantitative composition should be taken from the applicable approved labeling and regulatory dossier before a development or licensing decision.

The commercial significance of the SR formulation is greater than that of the immediate-release tablet because generic development must address:

• Extended-release dissolution across multiple pH conditions.
• Particle-size distribution and pellet coating uniformity.
• Dose proportionality across 225 mg, 325 mg, and 425 mg strengths.
• Food-effect performance.
• Alcohol-induced dose dumping risk.
• In-vitro and in-vivo release correlation.
• Bioequivalence over the full dosing interval.
• Manufacturing control of coating weight gain and membrane permeability.

How does the Rythmol excipient strategy control release?

The immediate-release formulation relies on rapid wetting, tablet disintegration, and drug dissolution. The SR formulation uses multiparticulate release control to reduce peak-to-trough fluctuation and permit twice-daily dosing.

Propafenone has high pharmacokinetic variability because its metabolism is affected by CYP2D6, CYP3A4, and CYP1A2 activity. The FDA label warns that increased propafenone exposure can result from CYP2D6 deficiency or coadministration with metabolic inhibitors.[1,2] That variability increases the commercial value of a formulation that provides reproducible release but also makes formulation changes clinically sensitive.

Key excipient design variables

A developer evaluating a Rythmol-equivalent product should prioritize:

1. Release-polymer selection. Hypromellose, ethylcellulose, acrylic polymers, and related coating systems can alter release duration and pH dependence.

2. Polymer loading. Small changes in coating weight or matrix concentration can materially shift the dissolution profile.

3. Surfactant level. Surfactants can improve wetting but may accelerate release or change permeability of a coated pellet.

4. Lubrication. Excess magnesium stearate can reduce wetting and slow dissolution.

5. Particle-size control. Active and excipient particle-size distribution affects blend uniformity, coating efficiency, and content uniformity.

6. Moisture management. Moisture can alter polymer hydration, capsule-shell behavior, granule strength, and long-term dissolution.

7. Capsule-shell selection. Gelatin and hypromellose capsules can show different moisture-transfer characteristics and mechanical performance.

What commercial opportunities exist for Rythmol excipients?

The strongest opportunity is a generic or differentiated propafenone product rather than a premium excipient sale into the existing brand. Rythmol and Rythmol SR have long-established active-ingredient chemistry, so commercial value depends on regulatory execution, manufacturing efficiency, and formulation performance.

Generic immediate-release tablets

Immediate-release propafenone tablets are the lowest-complexity entry point. A manufacturer can use widely available excipients and pursue an ANDA based on pharmaceutical equivalence and bioequivalence.

Potential advantages include:

• Lower tooling and equipment requirements.
• Standard wet granulation or direct-compression processing.
• Multiple strength presentations using a common formulation platform.
• Broad availability of compendial excipients.
• Lower development costs than extended-release capsules.

The principal commercial constraint is market size. Propafenone is a specialist cardiovascular product with lower unit demand than mass-market antihypertensive or anticoagulant products. Profitability depends on manufacturing scale, supply reliability, and the number of active generic competitors.

Generic extended-release capsules

Rythmol SR is a more attractive technical opportunity because the release-control system creates higher development barriers. A successful product may obtain better pricing and face fewer initial competitors than an immediate-release tablet.

A commercial developer can pursue:

• A direct generic Rythmol SR capsule.
• A multiparticulate capsule with a non-infringing coating system.
• A sprinkle formulation for patients with swallowing difficulty, subject to regulatory support.
• A smaller capsule platform using higher drug loading.
• A formulation with improved resistance to food-related release changes.
• A manufacturing process that reduces coating time and solvent consumption.

The principal risk is bioequivalence failure. A formulation can match single-dose pharmacokinetic parameters while showing dissolution differences that create regulatory concerns, particularly for an extended-release antiarrhythmic.

Excipient supplier opportunities

Excipient suppliers can target four areas:

Opportunity	Relevant excipient platform	Buyer value
Immediate-release tablet	Microcrystalline cellulose, starch, sodium starch glycolate, lubricants	Lower-cost compression and reliable disintegration
Extended-release pellet	Hypromellose, ethylcellulose, acrylic polymers	Controlled release and scalable coating
Capsule performance	Gelatin or hypromellose shells, moisture-control systems	Consistent fill weight and stability
Solubility and wetting	Polysorbates, sodium lauryl sulfate, coprocessed excipients	Improved dissolution and process robustness

The most defensible supplier position is a complete formulation package supported by dissolution data, stability data, and scale-up experience. A commodity excipient without regulatory support has limited differentiation.

What formulation patents protect Rythmol and Rythmol SR?

The original propafenone composition and early formulation rights are mature. The relevant commercial question is whether a specific generic formulation remains exposed to an unexpired formulation, process, or method-of-use patent.

Patent and exclusivity position

IP category	Rythmol relevance	Current commercial effect
Propafenone compound patents	Historically important	Core rights are expired or commercially exhausted
Immediate-release composition patents	Limited current leverage	Generic tablets are established
Extended-release formulation patents	Historically more important	Design-around and claim review remain necessary
Method-of-use patents	May cover treatment populations or dosing	Must be assessed against proposed labeling
Manufacturing patents	May cover pellet coating or process parameters	Can affect process selection and freedom to operate
Regulatory exclusivity	No biologic exclusivity framework	ANDA pathway is available for eligible products

The Orange Book should be reviewed for current Rythmol and Rythmol SR listings, patent expiration dates, and any certifications associated with approved generic products.[3] FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations identifies approved generic propafenone products and their therapeutic-equivalence ratings.[4]

What is the FDA regulatory pathway for propafenone generics?

Immediate-release propafenone tablets and extended-release capsules are generally developed through the ANDA pathway under Section 505(j) of the Federal Food, Drug, and Cosmetic Act.

Regulatory requirements

A generic developer must demonstrate:

• Pharmaceutical equivalence.
• Bioequivalence.
• Adequate manufacturing controls.
• Stability through the proposed shelf life.
• Appropriate labeling.
• Compliance with current good manufacturing practice.
• Control of impurities, residual solvents, and elemental impurities.
• Compatibility of the formulation with the selected container-closure system.

For Rythmol SR, regulatory complexity is higher because the applicant must reproduce the reference product’s extended-release performance. Comparative dissolution should be conducted across relevant pH media and, where appropriate, under fed and fasted conditions.

Paragraph IV challenges

A Paragraph IV certification may be relevant when an ANDA applicant believes an Orange Book-listed patent is invalid, unenforceable, or not infringed. The commercial value of a Paragraph IV strategy depends on:

• The number and remaining term of listed patents.
• Whether the patent claims the dosage form, formulation, method of use, or manufacturing process.
• The likelihood of a 30-month stay following litigation.
• The availability of a non-infringing formulation.
• The expected first-filer economics.

For mature propafenone products, the litigation opportunity is likely narrower than for newer small-molecule products. The main exposure is formulation-specific, particularly for extended-release capsules.

Which companies are competing in propafenone?

The competitive landscape includes the brand owner, authorized or independent generic manufacturers, contract manufacturers, and excipient suppliers. Propafenone products may be supplied by multiple generic companies depending on market and time period.

The relevant competitive dimensions are:

• FDA approval status.
• Therapeutic-equivalence rating.
• Current wholesaler supply.
• Number of active National Drug Codes.
• Strength coverage.
• Backorder history.
• Manufacturing site reliability.
• Wholesale acquisition cost and contract pricing.
• Ability to supply all dosage strengths.

A new entrant should not assume that an approved generic listing guarantees commercial access. Antiarrhythmic products can have concentrated demand, limited stocking by wholesalers, and abrupt pricing changes when one supplier exits.

How strong is the patent estate for Rythmol?

The Rythmol patent estate is weak for blocking the active ingredient but potentially more relevant for specific extended-release implementations.

Patent-strength assessment

Asset type	Relative strength	Commercial assessment
Propafenone active ingredient	Low	Mature generic competition
Conventional tablet excipients	Low	Easy design-around
Multiparticulate extended release	Moderate	Depends on claim scope and expiration
Specific coating composition	Moderate	Can be avoided through polymer or process changes
Manufacturing process	Variable	Relevant if claims are broad and difficult to design around
Method of use	Variable	Depends on label language and patent term
Trade secrets	Moderate	Process know-how may remain valuable even without patent protection

The strongest practical barriers are usually process reproducibility and regulatory evidence, not basic excipient ownership. A competitor that develops an alternative coating system can often reduce patent exposure, but it must still meet the reference product’s dissolution and pharmacokinetic profile.

What generic launch scenarios exist for Rythmol?

Immediate-release launch

An immediate-release entrant can launch through standard ANDA approval if no enforceable patent or exclusivity barrier remains. The likely commercial model is low-cost supply with limited differentiation.

Extended-release launch

An SR entrant has three possible strategies:

1. Direct generic substitution. The product matches the reference release profile and seeks therapeutic equivalence.

2. Formulation design-around. The developer uses a different polymer, coating process, or pellet architecture while targeting equivalent exposure.

3. 505(b)(2) reformulation. A modified dosage form or administration method may use the existing clinical record while seeking differentiated labeling. This route is more expensive and requires a clear clinical and commercial rationale.

Authorized-generic or licensing strategy

A brand owner or generic company could pursue an authorized-generic arrangement, contract manufacturing, or regional licensing. The value of such an agreement depends on supply continuity, market exclusivity, and the ability to use existing manufacturing assets.

There is no biosimilar pathway for propafenone because it is a chemically synthesized small molecule, not a biologic. Biosimilar risk is therefore irrelevant; generic substitution risk is the applicable framework.

How does Rythmol compare with competing antiarrhythmic products?

Propafenone competes with flecainide for rhythm-control treatment in selected patients. It also competes indirectly with sotalol, dofetilide, amiodarone, and catheter ablation.

Product	Formulation opportunity	Main commercial issue
Propafenone	IR tablet and ER capsule	Generic price pressure and pharmacokinetic variability
Flecainide	IR tablet and ER capsule	Similar specialist market and established generics
Sotalol	IR and IV products	Broader use but monitoring and safety constraints
Dofetilide	Capsule	Restricted initiation and hospitalization requirements
Amiodarone	Multiple dosage forms	Strong clinical use but toxicity limits long-term positioning

Propafenone’s most direct formulation comparison is flecainide. Both products have immediate-release and extended-release opportunities, but propafenone’s metabolism and active-metabolite profile increase the importance of exposure control.

What revenue exposure and market risks affect investment decisions?

Propafenone is unlikely to support a high-value standalone franchise based solely on conventional tablets. The more attractive investment case requires one of the following:

• A scalable extended-release platform.
• A low-cost manufacturing advantage.
• A reliable supply position in a constrained generic market.
• A differentiated administration format.
• A regional licensing or authorized-generic arrangement.
• A broader cardiovascular portfolio that shares manufacturing infrastructure.

Revenue risk comes from generic price erosion, low patient volume, wholesaler concentration, and the possibility that one or more competitors can replicate the formulation quickly. Supply interruptions can create short-term pricing opportunity but are difficult to forecast and should not be treated as a durable moat.

Key Takeaways

• Rythmol contains propafenone hydrochloride and is marketed as immediate-release tablets and Rythmol SR extended-release capsules.
• Immediate-release tablets use conventional fillers, disintegrants, binders, lubricants, and coating excipients.
• Rythmol SR has greater formulation value because multiparticulate release control raises development and scale-up barriers.
• The core propafenone patent estate is mature. Remaining risk is more likely to arise from formulation, process, or method-of-use claims.
• Generic tablets are a lower-cost entry opportunity with limited differentiation.
• Extended-release capsules offer greater technical and commercial upside but carry higher bioequivalence and manufacturing risk.
• Excipient suppliers should compete through formulation packages, dissolution support, and scale-up data rather than commodity supply alone.
• Propafenone has generic substitution risk, not biosimilar risk.
• The most attractive commercial strategy combines extended-release expertise with reliable supply and a broader cardiovascular product portfolio.

FAQs About Rythmol Excipients and Commercialization

What is the main excipient opportunity in Rythmol SR?

The main opportunity is the controlled-release pellet or multiparticulate platform. Polymer selection, coating uniformity, moisture control, and dissolution performance have greater value than conventional tablet excipients.

Can a generic company use the same excipients as Rythmol?

Yes, a generic company may use the same excipients if the formulation meets regulatory requirements and does not infringe an enforceable patent. The applicant must establish pharmaceutical quality and bioequivalence.

Is propafenone a narrow-therapeutic-index drug?

Propafenone has clinically important exposure variability and serious cardiovascular safety risks. Developers should apply strict control of dissolution, content uniformity, impurities, and pharmacokinetic performance even if the product is not treated as a formal narrow-therapeutic-index drug for every regulatory purpose.

Does Rythmol have biosimilar competition?

No. Propafenone is a chemically synthesized small molecule. Competition occurs through generic drug applications, not biosimilar applications.

What is the best commercial entry point for a new manufacturer?

The best entry point is usually an extended-release propafenone capsule with a robust, scalable multiparticulate process, provided the developer can demonstrate bioequivalence and secure dependable commercial supply. Immediate-release tablets offer simpler development but lower differentiation.

References

1. U.S. Food and Drug Administration. (2023). Rythmol (propafenone hydrochloride) tablets: Prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2023). Rythmol SR (propafenone hydrochloride) extended-release capsules: Prescribing information. FDA/DailyMed.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

5. U.S. Food and Drug Administration. (2022). Generic drug user fee amendments: Product-specific guidances and ANDA requirements. FDA.

6. U.S. Food and Drug Administration. (2023). Inactive ingredient database. FDA.